- Conditions
- Coronary Artery Stenosis
- Interventions
- State-of-the-Art Percutaneous Coronary Intervention, standard CABG
- Procedure
- Lead sponsor
- Duk-Woo Park, MD
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Palo Alto, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19
- Interventions
- Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
- Biological · Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
- Conditions
- Acute Myocardial Infarction
- Interventions
- Post Conditioning + Primary PCI, Standard Primary PCI
- Procedure
- Lead sponsor
- Minneapolis Heart Institute Foundation
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hip Pain Chronic
- Interventions
- Transmuscular Quadratus Lumborum Block, Pericapsular injection, Bupivacaine Hydrochloride
- Procedure · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myocardial Infarction
- Interventions
- MCC-135
- Drug
- Lead sponsor
- Tanabe Pharma Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Myocardial Infarction
- Interventions
- Tenecteplase, PCI
- Drug · Procedure
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,671 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Fort Lauderdale, Florida • St. Petersburg, Florida + 5 more
- Conditions
- Cardiovascular Diseases, Coronary Artery Disease
- Interventions
- OCT-NIRAF, LUMISIGHT Injection, OCT-NIRAF following LUMISIGHT Injection
- Device · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts